A Study on the Application and Use of Artificial Intelligence to Support Drug Development

被引:53
|
作者
Lamberti, Mary Jo [1 ]
Wilkinson, Michael [1 ]
Donzanti, Bruce A. [2 ]
Wohlhieter, G. Erich [3 ]
Parikh, Sudip [4 ]
Wilkins, Robert G. [5 ]
Getz, Ken [1 ]
机构
[1] Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Genentech Inc, Global Pharmacovigilance Innovat Policy, San Francisco, CA 94080 USA
[3] Amgen Inc, Digital Hlth & Innovat, Thousand Oaks, CA USA
[4] Drug Informat Assoc Amer, Washington, DC USA
[5] QPS Consulting LLC, Ashburn, VA USA
关键词
AI; artificial intelligence; drug development; machine learning; technology;
D O I
10.1016/j.clinthera.2019.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future. Methods: A 2-part method was used that comprised in-depth interviews with AI industry experts and a global survey conducted across pharmaceutical and biotechnology organizations. Eleven in-depth interviews focused on use and implementation of AI across drug development. The survey assessed use of AI and included perceptions about current and future use. The survey also examined technology definitions, assessment of organizational and personal AI expertise, and use of partnerships. A total of 402 responses, including data from 217 unique organizations, were analyzed. Findings: Although 7 in 10 respondents reported using AI in some capacity, a wide range of use was reported by AI type. Patient selection and recruitment for clinical studies was the most commonly reported AI activity, with 34 respondents currently using AI for this activity. In addition, identification of medicinal products data gathering was the top activity being piloted or in the planning stages, reported by 49 respondents. The study also revealed that the most significant challenges to AI implementation included staff skills (55%), data structure (52%), and budgets (49%). Nearly 60% of respondents noted planned increases in staff within 1-2 years to support AI use or implementation. Implications: Despite the challenges to AI implementation, the survey revealed that most organizations use AI in some capacity and that it is important to the success of an organization's workforce. Many organizations reported expectations for increasing staff as implementation of AI expands. Further research should examine the changing development landscape as the role of AI evolves. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:1414 / 1426
页数:13
相关论文
共 50 条
  • [31] Study of the use and contribution of artificial intelligence to the operation in electric power girds
    Ortiz-Torres, Luisferney
    Gomez-Luna, Eduardo
    Marles-Saenz-Jerez, Eduardo
    UIS INGENIERIAS, 2024, 23 (02): : 31 - 46
  • [32] Addressing COVID-19 Drug Development with Artificial Intelligence
    Ho, Dean
    ADVANCED INTELLIGENT SYSTEMS, 2020, 2 (05)
  • [33] Using Artificial Intelligence for Drug Discovery: A Bibliometric Study and Future Research Agenda
    Karger, Erik
    Kureljusic, Marko
    PHARMACEUTICALS, 2022, 15 (12)
  • [34] Impact of Artificial Intelligence on Drug Development and Delivery
    Aundhia, Chintan
    Parmar, Ghanshyam
    Talele, Chitrali
    Shah, Niyati
    Talele, Dipali
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2024,
  • [35] The Application of Artificial Intelligence in the Diagnosis and Drug Resistance Prediction of Pulmonary Tuberculosis
    Liang, Shufan
    Ma, Jiechao
    Wang, Gang
    Shao, Jun
    Li, Jingwei
    Deng, Hui
    Wang, Chengdi
    Li, Weimin
    FRONTIERS IN MEDICINE, 2022, 9
  • [36] Artificial Intelligence in Drug Treatment
    Romm, Eden L.
    Tsigelny, Igor F.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60, 2020, 60 : 353 - 369
  • [37] Artificial Intelligence for Drug Discovery
    Tang, Jian
    Wang, Fei
    Cheng, Feixiong
    KDD '21: PROCEEDINGS OF THE 27TH ACM SIGKDD CONFERENCE ON KNOWLEDGE DISCOVERY & DATA MINING, 2021, : 4074 - 4075
  • [38] New trends in the development and application of artificial intelligence in food processing
    Barthwal, Riya
    Kathuria, Deepika
    Joshi, Saloni
    Kaler, R. S. S.
    Singh, Narpinder
    INNOVATIVE FOOD SCIENCE & EMERGING TECHNOLOGIES, 2024, 92
  • [39] The application of artificial intelligence in health communication development: A scoping review
    Weingott, Sam
    Parkinson, Joy
    HEALTH MARKETING QUARTERLY, 2025, 42 (01) : 67 - 109
  • [40] The application and use of artificial intelligence in cancer nursing: A systematic review
    O'Connor, Siobhan
    Vercell, Amy
    Wong, David
    Yorke, Janelle
    Fallatah, Fatmah Abdulsamad
    Cave, Louise
    Chen, Lu-Yen Anny
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2024, 68